H.C. Wainwright reiterates Buy on Tscan stock, $7 target By Investing.com

H.C. Wainwright reiterated a Buy and $7 price target on TScan Therapeutics versus the current share price of $1.06 (implying ~560% upside). TScan completed enrollment for Cohort C of its Phase 1 ALLOHA trial with a commercial-ready manufacturing process and received FDA IND clearances for TSC-102-A01 and TSC-102-A03, targeting a Phase 1 start in H2 2026. Three analysts have raised earnings estimates recently, though the company is noted to be burning cash; VP Finance Leiden Dworak resigned effective April 10, 2026 and CFO Jason Amello will assume principal accounting officer duties.

Analysis

Intel’s visible uplift from a high-profile cloud AI partner is less about a single contract and more about de-risking a shift in hyperscaler procurement away from incumbent accelerators. That can meaningfully compress total addressable margin for standalone GPU vendors over 2–4 quarters as server OEMs re-spec boards and memory stacks around new x86+accelerator combos, lifting proximal suppliers (server boards, HBM, NICs) while pressuring entrenched pricing power downstream.

For the small-cap immuno-oncology name, the market is treating upcoming clinical signals as a binary re-pricing lever centered on two orthogonal proofs — deep molecular clearance plus sustained biological remodeling. The real valuation step-change requires durability far beyond transient responses; absent clear evidence of durable chimerism and 12+ month signal persistence, upside is likely to be muted and funding/dilution risk will reassert quickly.

Second-order operational risks matter: commercial-ready manufacturing at scale is the bottleneck that turns clinical signals into partner interest and royalties. For both themes, supply-chain readiness (CDMOs for cell therapy; motherboard/fab capacity and memory supply for datacenter CPUs) sets a 6–18 month delivery window for realized earnings, creating a lag between announcement and cash flow.

Key downside vectors are asymmetric: for the AI hardware trade, a delayed server deployment cycle or renewed GPU lead would compress gains within a quarter; for the biotech, a durability miss or a string of manufacturing Quality events triggers rapid derating and raises near-term financing needs. Monitor filing/QA flags and vendor backlog metrics as high-frequency indicators for conviction changes.

Key Decisions for Investors

• Long-dated call-spread on INTC (6–12 month expiries): buy a modest-sized 0.5–1% portfolio allocation call debit spread to capture an acceleration in datacenter CPU procurements. Target 2–4x upside if server wins translate to visible orders; stop-loss at ~35% of premium if order flow signals remain absent after two quarters.
• Relative-value pair: long INTC versus hedge with short near-term calls on a large-cap GPU/accelerator name (size the hedge ~25–50% of the INTC position). Rationale: capture asymmetric rerating of CPU content while limiting exposure if GPU pricing power persists. Time horizon 3–9 months; expect 20–30% gross move to make trade profitable.
• Event-driven asymmetric position in the small-cap biotech: small equity stake (<=1% portfolio) paired with an OTM protective put or bought call depending on options liquidity, sized to limit downside to ~30–40% of the stake. If options are thin, use a buy-and-hedge-with-warrants/collared structure. Objective: 5x+ upside on positive durable signal vs capped loss on negative outcome; monitor cash runway indicators and be ready to scale back on any financing announcement.
• Income-finance overlay for AI-exposed mega-cap (GOOGL/GOOG): sell near-term covered calls against a small baseline long to monetize inflated AI implied vol while retaining exposure to longer-term secular upside. Keep covered-call strikes at a 5–10% premium and roll monthly; suitable for investors who want carry while avoiding paying full implied volatility for multi-quarter AI upside.
• Risk management: for the biotech trade, buy a small put-spread as insurance ahead of any clinical/mfg updates if no options are available, and set an auto-exit on any announced financing or material manufacturing inspection within 7 trading days. For AI hardware trades, watch server OEM backlog and memory spot prices weekly; if both reverse >20% from recent levels, reduce exposure by half within 10 trading days.